SecBot SecBot
SC 13G/A ·Filed Nov 12, 2026

SLN

Silence Therapeutics plc
NEUTRAL
Impact 3/10
Horizonmonths Processed4d 14h ago SEC0002005369-26-000060
Passive stake amendment
Actionable Insight • Neutral

The reduction below 5% removes the requirement for future 13G filings by Invus, but the passive nature and small decrease suggest no strategic shift. Monitor for any further selling ahead of the Merck KGaA acquisition close in Q1 2027.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$19.80
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.15%
T+1 · $19.83
Vs SPY
+0.51%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $19.80entry
  2. T+1 · 4d ago +0.15%α +0.51% · $19.83
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invus Global Management and affiliated entities filed an amended Schedule 13G disclosing a 4.6% aggregate beneficial ownership stake in Silence Therapeutics plc as of September 30, 2026, down from a prior 5.2% stake. The filing confirms a passive investment intent with no activist purpose.

Key Financial Metrics

Stake
4.6%
Investor
Invus Global Management, LLC
Investor Type
hedge fund

Key Facts

  • Invus entities hold 8,663,601 ordinary shares (4.6% of 186,609,072 shares outstanding as of October 15, 2026)
  • Stake decreased from 5.2% in prior filing (October 13, 2026) to 4.6%
  • Invus Public Equities holds 7,591,233 shares (4.1%), Avicenna Fund holds 1,072,368 shares (0.6%)
  • Filing confirms passive investment under Rule 13d-1(c) with no control intent
  • Filing coincides with Silence Therapeutics' pending acquisition by Merck KGaA, expected to close Q1 2027

Financial Impact

Stake reduction from ~5.2% to 4.6% represents a decrease of approximately 0.6 percentage points of beneficial ownership

ownership_percentage

Risk Factors

  • Stake reduction could signal reduced conviction ahead of the pending acquisition
  • No material financial impact expected given the small size of the decrease

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0002005369-26-000060
Document: 0002005369-26-000060-index.html0002005369-26-000060
Document: 0002005369-26-000060.txt0002005369-26-000060

Track record

15 reports on SLN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Viewing Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026